• Is now the time to sell your ASX shares?

    laptop keyboard with red sell button

    The ASX has had a tremendous run over the past few months. Since its lows in late-March the S&P/ASX200 Index (ASX:XJO) has surged nearly 37%. However, in my opinion there are a few headwinds that could be facing investors in the near future. Here are some factors to take into consideration when deciding whether or not to sell your ASX shares.  

    Have ASX shares run too far?

    Around 4 months ago during the height of market volatility, many investors were unsure how companies would ever recover, let alone ever trade at all time highs again. What has transpired over the last few months has been astounding, with some ASX shares making once in a lifetime moves.

    A great example of this is Afterpay Ltd (ASX: APT), which hit a low of $8.90 in late March. Many investors questioned how buy now, pay later users would be able to meet their repayment obligations. Despite the pessimism, government income support and the rush to online and cashless retail has fuelled demand for the company’s services.

    These moves have not been limited to technology companies, with online retailers like Kogan.com Ltd (ASX: KGN) and meal-kit provider Marley Spoon AG (ASX: MMM) also harnessing the change in consumer behaviour.

    Despite government stimulus and certain companies buoying the overall market, many investors might be looking to take profits after such a miraculous run. A gloomy budget deficit, high unemployment forecasts and the looming reporting season could also serve as catalyst for a pullback.

    Be wary of the upcoming reporting season

    The upcoming reporting season in August is set to be one of the most complex and volatile seasons in recent history. The United States reporting season, which is currently underway, has provided a glimpse of the uncertainty and volatility Australian investors can expect.

    Heading into reporting season, many investors would be relatively optimistic given there have not been a significant number of earnings downgrades. However, like all reporting seasons, there are bound to be some surprises.

    What to watch this reporting season

    It will be interesting to see how companies disclose the impact of the pandemic to investors and how the market will react. Furthermore, with many ASX companies implementing cost-cutting strategies to protect their balance sheets, it will also be fascinating to see how dividend payout ratios are impacted. Shares in the travel sector are already expected to report badly whereas there is more optimism for shares in the health sector. Reporting season will provide an opportunity to find out exactly how the pandemic has impacted the bottom line of companies in the tech sector. Meanwhile, the results for ASX bank shares are also likely to provide good insight into the country’s recovery prognosis.

    Foolish takeaway

    As a long-term investor I would usually advocate for shareholders to stay invested through the regular troughs and peaks of the sharemarket. However, the share price moves and general market volatility we have seen during the pandemic are an anomaly. Rather than selling the lot, another prudent strategy investors could adopt would be to sell a portion of their holdings to lock in profits. This would keep them invested whilst also freeing up some capital to take advantage of more opportunities that could arise during the August reporting season. 

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of June 30th

    More reading

    Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Kogan.com ltd. The Motley Fool Australia owns shares of AFTERPAY T FPO. The Motley Fool Australia has recommended Kogan.com ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Is now the time to sell your ASX shares? appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3f1bqOy

  • 3 reasons why the Macquarie share price could be a buy

    macquarie share price

    In this article I’m going to tell you about three reasons why the Macquarie share price could be a buy.

    Macquarie is an investment bank that can trace its history back to 1969. It’s now one of Australia’s largest businesses with a market capitalisation of around $45 billion according to the ASX.

    The business boasts of a record of 51 years of unbroken profitability. That’s a very solid record for a financial business in my opinion.

    The Macquarie share price has recovered strongly since March 2020 – it’s up almost 75% since 23 March 2020 after the 52.5% drop to $72.

    But is it a still a buy? I think there are three reasons why I’d consider the Macquarie share price over other ASX blue chip shares:

    International earnings

    Plenty of the biggest businesses on the ASX are mostly focused on the domestic economy like the banks, Telstra Corporation Ltd (ASX: TLS), Coles Group Limited (ASX: COL) and Wesfarmers Ltd (ASX: WES).

    Macquarie only generates a third of its income from Australia and New Zealand. Meaning that international income account for two thirds of the business. The Americas accounted for a quarter of income in FY20, Asia made up 13% of total income and EMEA (Europe, the Middle East and Africa) accounted for 29% of total income. Macquarie’s share price would be nowhere near as high today without the international earnings. 

    I think that’s very important. The economies of Australia and New Zealand are sizeable, but obviously the entire world’s economy is much larger. So it’s better to be able to service the entire globe. It means Macquarie can invest into any region it wants to, wherever it thinks will produce the best return for its money.

    Diversified divisions

    Macquarie is probably one of the most diverse businesses among the ASX 20. It has four main segments: Macquarie Asset Management (MAM), banking and financial services, Macquarie Capital and commodities and global markets. The earnings diversification has been helpful for the recovery of the Macquarie share price this year in my opinion. For example, IPOs have dropped off but ASX capital raisings have been frequent. 

    Plenty of ASX shares are reliant on just one or two main sections to generate profit. But Macquarie makes good profit from each of its divisions. 

    Macquarie describes half of its business as ‘annuity style’, meaning it’s defensive and generates consistent income. That refers to MAM and the banking divisions. I’m not sure banking is particularly annuity-like – particularly during COVID-19 – but managing assets is a great earnings stream. Macquarie’s assets under management had grown to $606.9 billion at 31 March 2020. That’s a great benefit to Macquarie.

    The best bank

    I think Macquarie is by far the best large bank on the ASX.

    The big four ASX banks of Commonwealth Bank of Australia (ASX: CBA), Westpac Banking Corp (ASX: WBC), Australia and New Zealand Banking Group (ASX: ANZ) and National Australia Bank Ltd (ASX: NAB) are not terrible businesses – they just don’t offer much growth or earnings diversification. Loans are not a high-growth area and not very defensive. The Macquarie share price has recovered better than the big four ASX banks’.

    I wouldn’t want to diversify my portfolio by buying one of the big four because I believe it would lower my long-term investment returns. But Macquarie has proven it can be a good performer through the economic cycle.

    I think Macquarie also showed its quality through the Hayne royal commission. It barely featured whereas the big ASX banks had their reputations tarnished and had to repay large sums of money. 

    At this share price, is Macquarie a buy?

    I’d much rather buy Macquarie than most other blue chips due to its ability to grow anywhere. At the current Macquarie share price it’s trading at 16x FY22’s estimated earnings. I think that’s a reasonable price to pay for Macquarie shares considering a good amount of dividend income should be paid over the long-term as well, though the dividend is a bit uncertain due to COVID-19 at the moment. 

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of June 30th

    More reading

    Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited and Telstra Limited. The Motley Fool Australia owns shares of COLESGROUP DEF SET and Wesfarmers Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 3 reasons why the Macquarie share price could be a buy appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2Bunl9O

  • You should watch this key metric during the reporting season that others often overlook

    Share tips

    The upcoming profit reporting season will keep investors on the edge of their seats and you shouldn’t forget to scrutinise one often overlooked detail in the results.

    This is the cash conversion ratio, which most investors either do not know about or brush aside for earnings multiples and growth figures.

    Don’t get me wrong, price-earnings (P/E) ratios and sales and earnings growth are still important details this time round, as they are for every reporting season.

    Cash ratio as important as profit ratio

    But the cash conversion ratio (CCR) is particularly relevant in this COVID-19-stricken market. You’ll see why after I explain what this ratio is.

    The CCR measures the amount of cash a company collects as a percentage of earnings. Just because an ASX stock reports a $100 profit, it doesn’t mean it receives $100 in cash.

    Calculating the CCR is easy although few companies will do it for you when highlighting their profit and sales performance for the year.

    How to calculate the cash conversion ratio

    To get the ratio, you take the net operating cash flow (from the cash flow statement) and divide that by the reported earnings before interest, tax, depreciation and amortisation (EBITDA).

    Don’t get confused by the cash flow statement as it is broken into three sections – operations, investing and financing. Cash flow from operations reflects the cash a company gets from its ordinary business and what it pays to provide the service or products, and that’s the net figure you want.

    Some calculate the CCR by dividing the cash flow with net profits instead. I prefer to use the EBITDA number as amortisation and depreciation charges do not impact on cash and it produces a “cleaner” ratio.

    Why cash doesn’t match profit

    In the vast majority of cases, you will find that the net cash from operations falls short of EBITDA. This shortfall can be significant too and will vary from sector to sector.

    The general rule of thumb is that a company with a CCR of 80% or better is good. If the ratio falls below this, you should investigate why as it could be an early indication of a problem.

    So why does a company’s reported EBITDA not match the cash it receives? There are a few reasons for this. It could be a timing issue where a company recognises the profit from a sale before it gets paid by the customer.

    Another common reason is an expansion in the company’s working capital, perhaps to fund a build-up in inventory.

    Early warning sign

    That could be a bullish sign if management is expecting a big ramp up in near-term sales or is gearing up for the start of a big project.

    But in this coronavirus recessionary environment, a material increase in working capital could be a warning sign instead as most businesses will be experiencing declining sales.

    Further, many ASX companies are probably feeling a cash crunch from the COVID-19 fallout. Booking decent profits isn’t enough to stave-off a capital raising if the cash isn’t coming in fast enough.

    Final thoughts

    As I’ve written last week, capital raisings are one of the key features I am expecting during the reporting season. Paying attention to the CCR could provide an early clue of a company in need of fresh capital.

    As a final thought, the CCR is more relevant to S&P/ASX 200 Index (Index:^AXJO) companies than small caps.

    Market minnows often don’t have earnings and are still making losses. You can’t use the ratio if the EBIDTA number is negative.

    5 stocks under $5

    We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.

    And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    Motley Fool contributor Brendon Lau has no position in any of the stocks mentioned. Connect with me on Twitter @brenlau.

    The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post You should watch this key metric during the reporting season that others often overlook appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3htIOiC

  • Why investing in super can turbocharge your returns

    depositing coin into piggy bank for super, invest in super, grow super

    It’s the age-old question: should I be investing in super?

    The Aussie superannuation system can be divisive. Many, particularly the younger cohort, are reluctant to invest additional cash into their super funds.

    However, I’m a big believer in the power that super funds can have to turbocharge retirement plans.

    Here are a few reasons why investing more money in super can be a great idea for investors of all ages.

    Concessional contributions are taxed at 15%

    This is a really big factor in favour of investing in super. Concessional contributions up to $25,000 per year are taxed at just 15% by super funds.

    For reference, every dollar earned between $18,200 and $37,000 is taxed at 19%. Beyond that, Aussies are taxed progressively at 32.5%, 37% and up to 45% per dollar above $180,000 per year.

    That means investing in super as concessional contributions can generate a significant tax break. As a long-term investor myself, that seems like a no-brainer.

    I plan on using that money at 65+ anyway, so I might as well save some tax along the way.

    Investing in super means less tax on capital gains

    This is another big consideration but one that is often overlooked.

    A capital gains event generally occurs when an asset is sold. If that is outside of super and the asset has been held for over 12 months, the investor would get taxed at their marginal tax rate.

    However, capital gains within super get another handy tax break. During the accumulation phase, super funds typically receive a one-third discount on any capital gains made.

    Given super funds are taxed at the flat 15% rate, that means the capital gain would be taxed at effectively 10%.

    That’s compared to anywhere between 19% to 45% for investing outside of super if you earn upwards of $18,200 per year.

    Super funds can invest big and long-term

    Super funds have large pools of capital to invest across their various strategies. That means investing in super can get you access to investments that would otherwise not be possible.

    This includes allocations to private equity, hedge funds and infrastructure assets. These investments can generate liquidity premiums and boost overall returns.

    Investing in super is just one part of your strategy

    The good news is, it doesn’t have to be all or nothing when it comes to investing in your superannuation. You can still keep your investments outside of super, but you may need less of them.

    For instance, you could build up a sizeable portfolio of ASX shares or hold a broad market ETF like BetaShares Australia 200 ETF (ASX: A200) alongside your growing superannuation fund.

    If you retire early, you simply draw down your ETF holdings outside of super down to zero until preservation age.

    From there, your super investment kicks in and you can have a happy retirement.

    But… there are drawbacks

    Of course, if it was all good news, everyone would be investing more in super with no questions asked.

    The reality is that there is an opportunity cost of contributing more to your superannuation.

    That money is locked away for a long time and could be otherwise deployed elsewhere. For instance, you could buy ASX shares outside of super, pay down debt or save for a home deposit.

    The First Home Super Saver (FHSS) scheme does help to alleviate this in some sense, but not completely.

    There’s also a significant regulatory risk. Many investors worry that the preservation age will change by the time they retire.

    The government could also view super as a convenient way to pay back deficits through higher taxes.

    Foolish takeaway

    In the end, investing additional money in super is a personal choice. However, I think the benefits outweigh the potential risks for me as it currently stands.

    5 stocks under $5

    We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.

    And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Why investing in super can turbocharge your returns appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2WYE2St

  • Sorrento Therapeutics May Be Ready For a Pullback

    Sorrento Therapeutics May Be Ready For a PullbackSan Diego-based Sorrento Therapeutics (NASDAQ:SRNE) has become one of the hottest biopharmaceutical companies investors are watching in the rush to find a cure for the novel coronavirus. So far in the year, SRNE stock is up around 130%.Source: luchschenF / Shutterstock.com However, that number tells only half the story. In mid-March, Sorrento shares hit a recent low of $1.55. Now they are flirting with $8. That is an increase of about 400%.Put another way, $1,000 invested in SRNE stock in early spring would now be worth over $5,000.InvestorPlace – Stock Market News, Stock Advice & Trading TipsTherefore, today, I'll take a closer look at whether long-term investors should consider committing new capital into Sorrento Therapeutics. Why Investors Became Interested in SRNE StockSorrento is a clinical-stage and commercial biopharma company. Until recently, its emphasis was on immuno-oncology and non-opioid pain management. It has been working on therapies to "improve the lives of those who suffer from cancer [and] intractable pain." * 10 Cybersecurity Stocks We Need Now More Than EverThis year brought another dimension its efforts, i.e., its aggressive research on the novel coronavirus.The company claims that the immuno-oncology portfolio will allow it to develop multimodal therapies to "attack harmful cells frequently and relentlessly" and "generate the next generation of cancer therapeutics." In addition, it now has several Covid-19 therapy candidates.In fact, management is hopeful about having antibody ready by this fall. In recent weeks, SRNE stock has moved along with each news release by the company on the developments regarding their coronavirus-related trials.For example, following a press release on July 20, it surged close to 20%. The FDA gave the green light to Abivertinib for Phase 2 safety and efficacy study in hospitalized patients with moderate to severe Covid-19. The results would likely be important for patients "hospitalized with developing cytokine storm in the lungs." What Could Derail SRNE StockThe health and economic effects of the pandemic worldwide has fueled investors' love affair with small biotech firms as well as the big pharma.I'd encourage potential investors to read the company's latest 10-Q SEC filing where management highlights several important risk factors. It says, "We are a clinical stage company subject to significant risks and uncertainties, including the risk that we or our partners may never develop, obtain regulatory approval or market any of our product candidates or generate product related revenues."The next stage is in the efforts to develop a Covid-19 vaccine is expected to involve animal studies. And following potential successful results, human trials would be likely. However, the road is a long and potentially difficult one.Management also draws attention to the fact that it has "incurred significant losses since inception and [is likely to] incur continued losses for the foreseeable future." In the quarter that ended March 31, net revenue came $7.7 million. Net losses were more than $69 million.Developing effective therapies can be extremely costly, putting immense pressure, especially on a small company's capital structure. And the competition to develop a cure for the novel corona virus is intense. In addition to Sorrento, several other companies are currently working on vaccine or drug development. They include AstraZeneca (NYSE:AZN), GlaxoSmithKline (NYSE:GSK), Inovio Pharmaceuticals (NASDAQ:INO), Moderna (NASDAQ:MRNA), Novavax (NASDAQ:NVAX) and Pfizer (NYSE:PFE).It'd be important to remember that big pharma can not only discover a vaccine or drug, but also produce it in mass quantities, which is an essential part of the equation. Therefore, in the second half of the year, market participants may decide to de-risk away from smaller companies such as Sorrento.Instead, they may want to concentrate on more established names with established R&D and manufacturing facilities. Bottom Line for SRNE StockShares of many biotech companies, including SRNE stock, have seen stunning gains this year, especially since late March. Now market participants are wondering if they are somewhat late to the party or if the stock could indeed go up any further. Seasoned investors realize that big sums can be made or lost by taking a bet on a potential cure that may be developed by otherwise a small biotechnology company.Unless the company comes up with tangible results, some profit-taking in SRNE stock may be likely. Therefore, if you are an investor with paper profits, you may want to take some capital off the table.In the long run, if the company can successfully reach the finish line and develop a therapy that is accepted by global authorities, then early shareholders are likely to be rewarded even further. Potential long-term investors should appreciate the given risk/return profile of a small biotechnology company and remember that SRNE is a highly volatile stock. It makes rather substantial moves, both up and down on a daily basis.Finally, in case the company's efforts are successful, it could easily find itself a takeover candidate. Needless to say, such a development would benefit investors in SRNE stock.Tezcan Gecgil has worked in investment management for over two decades in the U.S. and U.K. In addition to formal higher education, including a Ph.D. in the field, she has also completed all 3 levels of the Chartered Market Technician (CMT) examination. Her passion is for options trading based on technical analysis of fundamentally strong companies. She especially enjoys setting up weekly covered calls for income generation. As of this writing, Tezcan Gecgil holds PFE covered calls (July 31 expiry). More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post Sorrento Therapeutics May Be Ready For a Pullback appeared first on InvestorPlace.

    from Yahoo Finance https://ift.tt/2CGOAyK

  • Replace your term deposit with these ASX dividend shares

    dividend shares

    At present the interest rates on offer with term deposits are at ultra low levels and struggling to keep up with inflation.

    In light of this, I suspect many income investors will be looking for suitable alternatives.

    But where can you turn? I think that ASX dividend shares could be the best way to replace your term deposit if you’re after reliable source of income. Especially given the generous yields on offer with many dividend shares right now.

    Three ASX dividend shares that I would buy are listed below. Here’s why I like them:

    Aventus Group (ASX: AVN)

    The first ASX dividend share I would suggest investors look at is Aventus. Although retail property companies are having a very difficult time during the pandemic, I’m optimistic that Aventus will be less impacted than others. This is because it specialises in large format retail parks and has a total of 20 centres across Australia. Its tenancies have a high weighting towards everyday needs and host high quality retailers such as ALDI, Bunnings, Officeworks, and The Good Guys. I believe this leaves it better positioned than most to ride out the storm. As a result, I estimate that Aventus shares could provide investors with a dividend yield of over 6% for FY 2021.

    Dicker Data Ltd (ASX: DDR)

    Another dividend share to consider buying is Dicker Data. It is a wholesale distributor of computer hardware and software across the ANZ region. Dicker Data has been a strong performer in FY 2020 and reported stellar growth during its recently completed first half, The company reported half year revenue above $1 billion for the first time and a 30.4% lift in net profit before tax to $42 million. In light of this, the company is on course to increase its dividend by 31% to 35.5 cents per share this year. Based on the current Dicker Data share price, this represents a generous fully franked 4.8% dividend yield.

    Telstra Corporation Ltd (ASX: TLS)

    A final ASX dividend share to consider buying is this telco giant. I think Telstra is one of the best dividend shares to buy on the ASX right now due to its defensive qualities and positive medium term outlook. Those defensive qualities have been on display for all to see this year. For example, at the height of the pandemic, Telstra was able to reaffirm its guidance for FY 2020. Importantly, this includes its free cash flow guidance for FY 2020. As a result, it appears perfectly positioned to continue paying a 16 cents per share fully franked dividend this year. And looking further ahead, I believe this dividend is sustainable for the foreseeable future thanks to its cost cutting, productivity improvements, and price increases. Based on the current Telstra share price, this dividend equates to an attractive 4.8% yield.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of June 30th

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Dicker Data Limited and Telstra Limited. The Motley Fool Australia has recommended AVENTUS RE UNIT. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Replace your term deposit with these ASX dividend shares appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2WVgyxv

  • Top brokers name 3 ASX shares to buy next week

    sign containing the words buy now, asx growth shares

    Last week saw a large number of broker notes hitting the wires once again. Three buy ratings that caught my eye are summarised below.

    Here’s why brokers think investors ought to buy them next week:

    Australia and New Zealand Banking GrpLtd (ASX: ANZ)

    According to a note out of Citi, its analysts have retained their buy rating and $24.75 price target on this banking giant’s shares. While the broker believes that the recent spike in coronavirus cases could mean further loan deferments, it isn’t enough to shift its positive view on the investment opportunity with ANZ’s shares. It continues to see value in its shares at the current level. I agree with Citi on ANZ and would be a buyer of them.

    Coca-Cola Amatil Ltd (ASX: CCL)

    Another note out of Citi reveals that its analysts have retained their buy rating and $9.85 price target on this beverage company’s shares. This follows the release of a trading update by Coca-Cola Amatil last week. It appears pleased with the volume recovery in the ANZ market and suspects volumes could surprise to the upside in the near term. And while it notes that its Indonesian business continues to struggle and has taken an impairment charge, it wasn’t overly surprised by this. While I’m not a huge fan of the company, I do think it could be worth a closer look.

    Tabcorp Holdings Limited (ASX: TAH)

    Analysts at UBS have retained their buy rating and lifted the price target on this gambling company’s shares to $5.00. According to the note, the broker’s research has shown a material increase in digital betting during the pandemic. Its analysts believe that Tabcorp has won a bit of market share thanks to its promotions. It feels this will offset some of the weakness it is experiencing in other parts of the business. Once again, it’s not a share that I’m naturally drawn to, but it could be worth considering.

    5 stocks under $5

    We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.

    And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Top brokers name 3 ASX shares to buy next week appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3g28l1Q

  • Barron’s Picks And Pans: Crispr, McDonald’s, Nikola And More

    Barron's Picks And Pans: Crispr, McDonald's, Nikola And More* This weekend's Barron's cover story examines the prospects for electric truck makers. * Other featured articles look at companies seeking a cure for sickle cell, risks associated with mortgage REITs and a bubble forming in hydrogen fuel-cell stocks. * Also, the prospects for a troubled California utility, a tobacco pick, a fast-food giant and more.Cover story "Electric Trucks Are the Future. The Stocks Are for the Bold." by Al Root suggests that though speculative fervor has sent shares of electric-truck makers like Nikola Corporation (NASDAQ: NKLA) soaring, competition is stiff and Tesla-like returns may prove elusive.Bill Alpert's "These Companies Are Seeking a Cure for Sickle Cell" points out that successful treatments would demonstrate the potential for gene therapy and boost biotech companies like Crispr Therapeutics AG (NASDAQ: CRSP).In "PG&E Looks Undervalued After Exiting Bankruptcy," Alexandra Scaggs shows why California utility PG&E Corporation (NYSE: PCG) is cheap relative to its peers, but it's difficult to assess how much of its discount is warranted.The Chevron Corporation (NYSE: CVX) acquisition of Noble Energy, Inc. (NASDAQ: NBL) appears to be a one-off, according to "The Pandemic Has Hit Oil Stocks. Chevron's Deal Isn't Enough to Change That" by Avi Salzman.In Bill Alpert's "There's a Bubble Forming in Hydrogen Fuel-Cell Stocks," see why Barron's thinks that stocks of Ballard Power Systems Inc (NASDAQ: BLDP), Plug Power Inc (NASDAQ: PLUG) and other makers of hydrogen fuel cells are in danger of jackknifing.See Also: Is Now The Time To Short Tesla's Stock?"Tobacco and ESG? One Cigarette Maker Sees a Perfect Match" by Jack Hough takes a look at why Philip Morris International Inc. (NYSE: PM), aiming to build a smoke-free future, recasts itself as an ESG (environmental, social and governance) play. Will investors buy it?Companies like Annaly Capital Management, Inc. (NYSE: NLY) use leverage to boost returns, and some have cut dividends due to the pandemic. So says Lawrence C. Strauss's "Mortgage REITs Carry Double-Digit Yields — and the Risks That Come With Such Yields."In "Americans Are Antsy. McDonald's Stock Could Get a Boost From the Drive-Through Window," Ben Levisohn makes a case that hard-hit Mcdonald's Corp (NYSE: MCD) stock could see improvement as Americans get sick of staying at home.See more from Benzinga * Barron's Picks And Pans: Biden, ESG And Reopening Picks * Barron's Picks And Pans: Brunswick, Cloudflare, Gilead And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    from Yahoo Finance https://ift.tt/2ZZ0rkd

  • Pelosi against extra jobless benefits temporary extension

    Pelosi against extra jobless benefits temporary extensionEvercore ISI Head of U.S. Public Policy and Political Strategy Research Sarah Bianchi joins Yahoo Finance’s Akiko Fujita to discuss the latest stimulus negotiations in Congress, as Republicans delay the unveiling of their $1 trillion stimulus plan to next week.

    from Yahoo Finance https://ift.tt/2BstXWe

  • Casino Stock Analyst Says Things Are Going From Bad To Worse In Vegas

    Casino Stock Analyst Says Things Are Going From Bad To Worse In VegasThe initial reopening of the Las Vegas Strip went relatively well for casino operators in early June, but abysmal room rates and a second wave of the COVID-19 outbreak seems to have eliminated hope that the Vegas recovery will continue any time soon.Las Vegas Sands Corp.(NYSE: LVS) management told investors this week that Vegas is suffering "a world of hurt," and the U.S. gaming hub has a long way to go in recovering from its shutdown, according to BofA Securities.The Numbers: Pricing of Las Vegas Strip hotel room rates for the month of August is now down 40% from a year ago. Pricing conditions on the Strip have worsened since June 12 when August rates were down just 31%. September prices are also down 37% year-over-year, suggesting little improvement heading into the fall.Vegas strip operators Las Vegas Sands, MGM Resorts International (NYSE: MGM), Wynn Resorts, Limited (NASDAQ: WYNN) and Caesars Entertainment Corporation (NYSE: CZR) are taking a hit from the plummeting room rates, BofA analyst Shaun Kelley said in a note.Las Vegas Sands recently closed the Palazzo back up for weekday reservations after midweek occupancy levels dropped to 25% or lower."We see little reason to think these operating challenges are exclusive to LVS and we have seen recent furloughs from WYNN in addition to layoffs at the Tropicana and Circus Circus," Kelley said Friday.Bleak Outlook: BofA estimates Las Vegas Sands will take the smallest hit on room rates in August, down 13% compared to a year ago. Kelley said Wynn will take the largest hit, with room rates down 52%.Las Vegas Sands management said this week there is no evidence investors should expect the city's group and convention business to return anytime soon.KAYAK flight search data for Las Vegas is reportedly down 68% from a year ago. Clark County, Nevada reported more than 1,000 new COVID-19 cases on Thursday for the fifth day in the past week.Benzinga's Take: The two biggest questions for Vegas casino stock operators at this point is will reopened casinos stay open and how long will it take for travelers to return?For long-term investors looking to play the recovery, Bank of America has the following ratings and price targets for major Las Vegas casino operators: * Las Vegas Sands, Buy rating and $61 target. * Wynn, Buy rating and $95 target. * MGM Resorts, Underperform rating and $15 target.Related Links:Analyst: End Of Quarantine Restrictions 'Very Positive For Our Macau Stocks'Analyst: 'Trends Are Encouraging' For US Regional CasinosSee more from Benzinga * What Are EV Regulatory Credits And Why Is Tesla Selling So Many Of Them? * This Day In Market History: The Liquidation Of Corporate Fraud ZZZZ Best * Tesla's Valuation Still 'Appears Overcharged' Following Q2 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    from Yahoo Finance https://ift.tt/2BqSCdI